CHM.AX Chimeric Therapeutics Limited
Company Analysis
Latest News
🟢 Chimeric Therapeutics is trading 5.6% up today on bargain hunting after recent weakness
Chimeric Therapeutics is trading 5.6% up at A$0.04 as the stock rebounds from recent selling pressure. • The move is being attributed to bargain hunting after...
🟢 Chimeric Therapeutics is trading 6% up today on bargain hunting after recent weakness
Chimeric Therapeutics is trading 6% up today at A$0.04 as the stock rebounds from recent selling pressure despite a lack of fresh corporate catalysts. • The...
🔴 Chimeric Therapeutics is trading 8% down today as it extends a slide amid light news flow and profit-taking
Chimeric Therapeutics is trading 8% down at A$0.04, extending a steady decline from A$0.05 over recent sessions amid light news flow and investor...
🔴 Chimeric Therapeutics is trading 7.1% down today amid ongoing investor caution
Chimeric Therapeutics is trading 7.1% down today at A$0.04 as the stock extends its recent slide from A$0.05 amid a lack of fresh catalysts. • No...
🟢 Chimeric Therapeutics is trading 9.1% up today on biotech rebound and short-covering
Chimeric Therapeutics is trading 9.1% up today at A$0.05 as the stock rebounds from recent weakness in small-cap biotechnology names. • The price action...
🔴 Chimeric Therapeutics is trading 8.3% down today on biotech sector weakness and profit-taking
Chimeric Therapeutics is trading at A$0.04, down 8.3% today, as the stock faces a sharp pullback driven by broader weakness across biotechnology names and...
🔴 Chimeric Therapeutics is trading 8.3% down today on sector weakness and profit-taking
Chimeric Therapeutics is trading at A$0.04 (-8.33%) following a sharp pullback driven by sector weakness and profit-taking. • The decline aligns with broader...
🔴 Chimeric Therapeutics is trading 6% down today on sector weakness and profit-taking
Chimeric Therapeutics is trading approximately 6% down today at A$0.05 as the stock pulls back despite reporting encouraging interim clinical data. • Phase 1...
Chimeric Therapeutics Reports 40% Tumor Shrinkage in Phase 1 GI Cancer Trial
Chimeric Therapeutics (ASX:CHM) released interim Phase 1 results for its CHM CDH17 CAR-T therapy targeting gastrointestinal cancers. Two of four patients at...
🔴 Chimeric Therapeutics is trading 11.8% down
Chimeric Therapeutics is trading at A$0.04, down 11.8% from a comparison close of A$0.05 during regular trading. This is a price-action follow-up, so a...
🟢 Chimeric Therapeutics is trading 7.7% up today on potential corporate transaction speculation
Chimeric Therapeutics is trading at A$0.06, up 7.7% today, following renewed investor focus on a potential corporate transaction highlighted in its recent...
🟢 Chimeric Therapeutics is trading 5.8% up today on speculation of a potential corporate transaction
Chimeric Therapeutics is trading at A$0.06 (+5.77%) as investor attention remains fixed on a potential corporate transaction following the company's recent...
Chimeric Therapeutics Launches Strategic Review and Shakes Up Its Board — But Can a A$3 Million Company Actually Attract a Meaningful Deal?
Shares shifted as Chimeric Therapeutics (ASX: CHM) edged up to A$0.06, gaining roughly 12% after the Australian cell-therapy developer announced on July 1 that...
🟢 Chimeric Therapeutics is trading 12% up today after strategic review and board changes
Chimeric Therapeutics is trading 12% up today at A$0.06 after announcing a strategic review and board changes aimed at maximizing shareholder value. • The...
🔴 Chimeric Therapeutics is trading 5.45% down today following board changes and strategic review announcement
Chimeric Therapeutics is trading at A$0.05, down 5.45% today following the announcement of a strategic review and changes to its board of directors. • The...
🔴 CHM.AX Dips 5% Amid Recent Board Changes and Strategic Review
• CHM.AX is trading at A$0.05 (-5.45%) following recent company developments. • Chimeric Therapeutics announced on July 6, 2026, that an independent...
🟢 CHM.AX is trading 5.3% up today as investors reassess its strategic review
CHM.AX is trading 5.3% up at $0.06 as investors reassess the impact of the company's strategic review and capital management plans. • The stock is rebounding...
🔴 CHM.AX falls 12.31% on July 1st following strategic review announcement
CHM.AX closed at $0.06 (-12.31%) on July 1, 2026, after Chimeric Therapeutics announced the appointment of Hawkesbury Partners as an Independent Financial...
🔴 CHM.AX makes sharp 15.4% drop
CHM.AX is trading at $0.06, down 15.4% versus the comparison close of $0.07 during regular trading. This is a price-movement alert; no separate...
🔴 CHM.AX is trading 7.7% down today with no clear company-specific news catalyst
CHM.AX is trading 7.7% down today at $0.06 with no fresh company-specific news or regulatory filings to explain the price movement. • The decline appears to...